1. Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience
   Jérémy Baude et al, 2024, Cancers CrossRef
2. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
   Benedikt Feuerecker et al, 2021, European Urology CrossRef
3. Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives
   Erman Akkus et al, 2024, Cancer Treatment Reviews CrossRef
4. Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment
   Norman J. Maitland et al, 2019, Human Cell Transformation CrossRef
5. Current concepts of neuroendocrine cancer of the prostate: a clinical case and review of the literature
   Grigoriy A. Chizh et al, 2022, Journal of Modern Oncology CrossRef
6. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
   Abir Salwa Ali et al, 2018, Medical Oncology CrossRef
7. Etoposide Loaded SPION‐PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis
   Merve Erkisa et al, 2020, Chemistry & Biodiversity CrossRef
8. DNA‐PKc inhibition overcomes taxane resistance by promoting taxane‐induced DNA damage in prostate cancer cells
   Olivia S. Chao et al, 2021, The Prostate CrossRef
9. Delineating the tumour-regulatory roles of EYA4
   Zhi Xiong Chong et al, 2023, Biochemical Pharmacology CrossRef
10. A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing
    Hiroshi Hongo et al, 2021, International Cancer Conference Journal CrossRef
11. When repeated biopsy dramatically changes treatment tactics in metastatic castration-refractory prostate cancer with neuroendocrine transformation: clinical case and literature review
    I. S. Usoltseva et al, 2024, Cancer Urology CrossRef
12. Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy
    Keitaro Watanabe et al, 2019, Clinical Genitourinary Cancer CrossRef
13. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
    Benedikt Feuerecker et al, 2023, Journal of Nuclear Medicine CrossRef